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Comparison of Long-Term Oral Anticoagulation Therapies 
Including Newly Approved Reversal Agent for Dabigatran 
Mackenzie De Vine, Natalie Lennartz, Michaela Wolford, Rebecca Worden, Joelle Farano, Erin Petersen, PharmD, BCPS 
Abstract 
Anticoagulants are a well-known class of agents essential for 
the prevention of blood clots, which may further develop into 
deep vein thrombosis, pulmonary embolism or stroke. Indi-
viduals at a high risk of clotting, such as those with atrial fi-
brillation, multiple risk factors or recent hip/knee surgery, 
are in need of long-term anticoagulation therapy. The pur-
pose of this review is to highlight the pros and cons for each 
available anticoagulant as well as discuss pivotal clinical tri-
als that evaluated the safety and efficacy of these agents. 
Warfarin, the oldest anticoagulant, requires the patient to 
attend frequent appointments with a health care profession-
al in order to test their international normalized ratio (INR). 
Newer anticoagulants, including dabigatran, rivaroxaban and 
apixaban, do not require frequent INR testing and have a 
quicker onset of action than warfarin, providing convenience 
for the patient. However, many health care professionals pre-
fer warfarin because the INR may indicate its efficacy, its 
dosages can be easily changed and it is typically more afford-
able. Additionally, dabigatran may be chosen because it is the 
only one of these drugs that has a reversal agent, which can 
be utilized in the case of major bleeding or emergent surgery. 
There are many opportunities for pharmacists to impact pa-
tient outcomes in the anticoagulation therapy setting. From 
clinics to the community pharmacy setting, the pharmacist's 
role in patient counseling and education is crucial in reduc-
ing mortality. Additionally, drug development is a growing 
market as reversal agents are needed for many of these new-
er anticoagulation therapies. 
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Introduction 
Thromboemboli often follow the abnormality of at least two 
of the three factors included in Virchow's triad.1 The triad 
includes hypercoagulability, stasis and vascular endothelial 
injury damage as the three most important anomalies in de-
termining a patient's risk of developing a blood clot. A 
CHADS2 score is used in atrial fibrillation patients to assess 
their risk for stroke and eligibility for anticoagulation thera-
py.2 Factors in this assessment include congestive heart fail-
ure (1 point), hypertension (1 point), age 75 years and older 
(1 point), diabetes mellitus (1 point), and prior stroke or 
transient ischemic attack (2 points). Anticoagulation therapy 
should be considered in patients scoring one point and 
should be recommended in patients scoring two or more 
points. Some thromboembolic disorders are congenital, 
innate or recurring.1 Risks factors of clot formation also 
include pregnancy, obesity, immobility for long periods of 
inactivity, smoking, oral contraceptives, trauma, surgeries, 
autoimmune disorders, hormone therapy, inflammatory 
disorders, age, heart valve replacements, postsurgery, con-
genital heart defects and other coagulation and heart-related 
disorders.1,3,4 With many risk factors, and the commonality of 
their prevalence, the need for an easily managed anticoagu-
lant therapy is important for many patients.4 
As described by the Virchow's triad, clot formation predominant-
ly occurs when the triad is compromised which is especially 
common after stasis and/or venous injury, two usual events that 
occur post-op.s Following vascular injury, factors of the coagula-
tion process become exposed and initiate the clotting cascade 
allowing platelets to adhere to vascular endothelium and be-
come activated. Upon activation, successive platelets aggregate 
via platelet adhesion receptors resulting in thrombus formation. 
The aggregation of clotting factors and platelets causes a 
blood clot which, if large enough, can cause blockage of blood 
flow through the vesseJ.s These clots can form in the periph-
eral extremities causing deep vein thrombosis (DVT) or can 
become dislodged and enter the lungs causing pulmonary 
embolism (PE). In the United States, venous thromboembo-
lism (VTE) causes more than 300,000 admissions to 
hospitals every year, and PEs are responsible for death in 
approximately 12 percent of hospitalized patients claiming 
the lives of 50,000 to 250,000 patients every year. 4 In a 
study conducted by O'Reilly, Burgess and Zicat including 
5,999 patients undergoing total knee replacement (TKR), 
total hip replacement (THR) or bilateral TKR while on DVT 
prophylaxis, the prevalence of DVT was 25.6 percent, 8.9 
percent and 36.9 percent, respectively.6 In the same study, 
symptomatic PE was present in 1.9 percent of all patients, 
and the prevalence of fatal in-hospital PE was 0.05 percent. 
Anticoagulant therapy is common in patients with atrial 
fibrillation (AF), a common type of heart arrhythmia.7 
Arrhythmias include the heart beating too fast, too slow or 
irregularly; more specifically, AF is caused by an irregular 
conduction of the atrial chambers allowing them to fibrillate. 
Atrial fibrillation increases the risk of stroke, which may be 
reduced with anticoagulation therapy. To prevent these seri-
ous outcomes, anticoagulant therapy can be very beneficial. 
The goal of this article is to summarize the various anticoag-
ulant therapies and emphasize the value of reversal agents, 
especially the new reversal agent, idarucizumab (Praxbind), 
for the anticoagulant dabigatran (Pradaxa®). 
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Warfarin 
Warfarin was approved in the United States in 1954, making 
it one of the oldest drugs still used therapeutically today.a 
Warfarin was discovered in the 1920s after a bout of cattle 
disease named "sweet clover disease."9 During the Great De-
pression, moldy hay, which unknowingly contained molds 
such as Penicillium nigricans and Penicillium jensi, was fed 
to cattle causing severe hemorrhagic bleeding resulting in 
death of the cattle. Two veterinary surgeons, Schofield and 
Roderick, found that avoiding the moldy sweet clover hay 
prevented the bleeding effects in cattle. Roderick later dis-
covered that the acquired coagulation disorder was caused 
by a "plasma prothrombin defect" and, for the next 10 years, 
farmers avoided feeding their cattle sweet clover hay in fear 
of the bleeding disorder. Eventually Karl Link and his stu-
dent, Wilhelm Schoeffel, isolated the causative agent that is 
now known as dicoumarol. Dicoumarol was found to be 
formed by oxidation of natural coumarin in the moldy hay. In 
1945, Link used the derivative as a rodenticide that killed 
rodents by causing internal hemorrhage. After success as a 
rodenticide, the transition to a compound with clinical appli-
cation under the name "Coumadin" began. 
Warfarin, the generic of Coumadin, is an anticoagulant that 
functions by competitively inhibiting the vitamin K epoxide 
reductase (VKOR) complex which works by reactivating inac-
tive vitamin K to active vitamin K, thus depleting active vita-
min K_10 With decreased active vitamin K, synthesis of active 
clotting factors is reduced causing diminished coagulation 
effects of the blood. 
Warfarin is approved for prophylaxis and treatment of 
thromboembolic complications, which include valvular and 
nonvalvular atrial fibrillation; mechanical prosthetic cardiac 
valves; prophylaxis and treatment of venous thrombosis and 
its extension, including PE; and as adjunct therapy in reduc-
ing the risk of systemic embolism following a myocardial 
infarction (MI).a.10 
Warfarin is dosed anywhere between 1 mg and 10 mg daily.a 
Dosing varies on hepatic impairment, vitamin K intake, 
chronic heart failure (CHF), age, and functional variants of 
CYP2C9 (*2 or *3 alleles) or VKORCl (-1639 polymor-
phism).10 Full therapeutic effects of warfarin are typically 
seen five to seven days after beginning therapy which gener-
ally requires bridging therapy overlap with low molecular 
weight heparin (LMWH) or unfractionated heparin for at 
least five days and with an international normalized ratio 
(INR) of 2 or higher for at least 24 hours. 
The major adverse reactions of warfarin are fatal and nonfa-
tal hemorrhage from any tissue or organ, and the most se-
vere are spontaneous intracranial hemorrhage (ICH) and 
gastrointestinal (GI) bleeding.10 Warfarin use should be 
avoided as the monotherapy in treating heparin induced 
thrombocytopenia (HIT) as warfarin initially inhibits the 
synthesis of Protein C, the body's own anticoagulant factor, 
and possibly accelerates the thrombotic process. Warfarin is 
considered pregnancy category D or X as warfarin crosses 
the placenta, and incidents of teratogenic effects have been 
reported in exposure after the first trimester, and central 
nervous system (CNS) events to the fetus have been ob-
served while taking warfarin in any trimester. In most cases, 
warfarin is contraindicated in pregnancy, except in women 
with mechanical heart valves where the possible benefits of 
warfarin should be weighed against the risks and risks/ 
benefits of switching to another anticoagulation therapy. 
Warfarin has a narrow therapeutic index, and several factors, 
including other medications and alterations in diet, can play 
a role in the extent of clotting factor inhibition; therefore, 
anticoagulation must be carefully monitored.a An INR in-
creased by 2 to 3.5 times normal should be achieved to bal-
ance between preventing thrombosis and avoiding major 
bleeding complications.ii International normalized ratio 
should be monitored at least every one to four weeks de-
pending on INR consistency or variations including recent 
warfarin dose, medication, disease and diet changes.a When 
other products that affect warfarin are initiated, discontin-
ued or taken irregularly, additional INR testing should be 
performed. It is also important to note that whole blood clot-
ting and bleeding times are not effective in measuring and 
monitoring warfarin therapy, and an INR greater than 4 gen-
erally does not provide an additional benefit and is often as-
sociated with increased bleeding risk.lo 
Before starting a new prescription or over-the-counter medi-
cation, a patient should discuss the risks with a trusted 
health care professional as some medications can affect INR 
and require more frequent blood testing.12 Patients should 
avoid aspirin, unless instructed otherwise by a physician, as 
this may increase a patient's bleeding risk. Other medications 
that can interact with warfarin include antibiotics, pain med-
icines such as nonsteroidal anti-inflammatory drugs 
(NSAIDs), and acid reflux medications such as cimetidine. 
Some foods may also alter the effects of warfarin.10 Excessive 
acute consumption of alcohol (binge drinking) should be 
avoided in patients taking warfarin as it decreases the me-
tabolism of oral anticoagulants and increases prothrombin 
time (PT) and INR, whereas, chronic alcohol use may in-
crease the metabolism of anticoagulants and decrease PT and 
INR. Patients taking warfarin should maintain a consistent 
diet because the effects of warfarin are decreased with an 
increase of vitamin K intake. Foods, especially green leafy 
vegetables, are high in vitamin K, and changes in ingestion of 
these foods may alter warfarin effects. Patients should do 
their best to take their warfarin medication at the same time 
every day to maintain consistency in their therapy. 
In cases of warfarin overdose, patients may have extensive 
bleeding requiring reversal. In excessive bleeding, warfarin 
should be discontinued and vitamin Ki may need to be ad-
ministered parenterally.a Urgent warfarin reversal may also 
require fresh frozen plasma (FFP) or prothrombin complex 
concentrates (PCC). The 2015 American Heart Association/ 
American Stroke Association (AHA/ASA) Guidelines on in-
tracerebral hemorrhage (ICH) compares FFP, PCC and re-
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combinant activated factor Vila (rFVIIa) as potential thera-
pies with the use of vitamin Kin reversal of warfarin induced 
over-anticoagulation.13 Congruent recommendations are 
found in the 2012 CHEST Guidelines on Evidenced-Based 
Management of Anticoagulant Therapy. The CHEST 
Guidelines advise the administration of vitamin K in over-
anticoagulated patients as follows: patients with an INR 
between 4.5 and 10 and no evidence of bleeding should not 
be given vitamin K, patients with an INR of 10 or higher with 
no evidence of bleeding should be given oral vitamin K, and 
patients with major bleeding associated with warfarin 
should undergo rapid reversal of anticoagulation with PCC 
rather than plasma and with vitamin K 5 mg to 10 mg admin-
istered by slow intravenous injection.2 
Dabigatran 
Dabigatran etexilate (Pradaxa), is a direct thrombin inhibi-
tor.14 It was approved by the U.S. Food and Drug Administra-
tion (FDA) in 2010 for use in DVT, PE, nonvalvular atrial fi-
brillation and postoperative thromboprophylaxis. Dabigatran 
etexilate is a prod rug which is converted into its active form, 
dabigatran. Dabigatran reversibly inhibits thrombin which is 
both free and fibrin-bound, preventing thrombin's endoge-
nous activity of cleaving fibrinogen to fibrin, activating clot-
ting factors V, VII, XI, Xlll and promoting platelet aggregation. 
The inhibition of these functions leads to the inhibition of 
clot formation. 
Four studies were credited with the approval of dabigatran 
by the FDA. The first study, Dabigatran versus Warfarin in 
the Treatment of Acute Venous Thromboembolism (RE-
COVER) was a randomized, double-blind, double-dummy, 
noninferiority trial comparing oral dabigatran to warfarin.1s 
Patients enrolled in the study had acute venous thromboem-
bolism and were initially treated with parenteral anticoagu-
lation medication for a median of nine days prior to the 
initiation of oral therapy with either dabigatran or warfarin. 
Dabigatran was dosed at 150 mg twice daily while warfarin 
was dosed per patient to achieve an INR between 2.0 and 3.0. 
The study included 2,550 patients with 1,275 patients in 
each treatment arm.1s Patients were started on oral therapy, 
assessed seven days later, and then continually checked once 
monthly for a total of six months. The primary outcome was 
the incidence of venous thromboembolism and related death. 
Within the six month treatment period, 30 patients in the 
dabigatran arm and 27 in the warfarin arm experienced the 
primary outcome. This was not a statistically significant dif-
ference, determining dabigatran's noninferiority to warfarin. 
Treatment of Acute Venous Thromboembolism with 
Dabigatran or Warfarin and Pooled Analysis (RE-COVER II) 
was a randomized, double-blind, double-dummy trial that 
was designed after the conclusion of the RE-COVER study to 
confirm the findings.16 The patients in the trial had been di-
agnosed with an acute venous thromboembolism and had 
been treated with heparin for five to 11 days prior to initia-
tion of the study. Dabigatran was dosed at 150 mg twice dai-
ly, and warfarin was dosed per patient to achieve an INR 
between 2.0 and 3.0. The primary outcome of the study was 
the recurrent incidence of venous thromboembolism and 
related death. Results of the study showed noninferiority of 
dabigatran to warfarin due to the 30 positive outcomes 
(recurrent venous thromboembolism and/or related death) 
of the dabigatran group and the 28 of the warfarin group. 
These treatment arms were not statistically significant prov-
ing noninferiority of dabigatran to warfarin. 
The Extended Use of Dabigatran, Warfarin or Placebo in Ve-
nous Thromboembolism (VTE) is an article compiling the 
results of the RE-MEDY and RE-SO NATE trials.17 RE-MEDY, a 
randomized and double-blind trial, treated patients with 
dabigatran 150 mg twice daily or with warfarin dosed per 
patient to achieve an INR between 2.0 and 3.0. The primary 
efficacy outcome was venous thromboembolism or related 
death. The study included 2,866 patients who had been diag-
nosed with VTE and treated with anticoagulation therapy for 
three months prior to initiation of the study. Within the 
study, 26 patients experienced a VTE or VTE-related death in 
the dabigatran arm and 18 patients in the warfarin arm. Alt-
hough the dabigatran treatment group produced more VTE 
or related deaths, the two treatment arms were not statisti-
cally significant, concluding that dabigatran was noninferior 
to warfarin. 
RE-SONATE, another randomized and double-blind trial, 
compared the treatment of 150 mg of dabigatran twice daily 
to placebo.17 The study included 1,343 patients previously 
diagnosed with a VTE and treated with anticoagulation ther-
apy for three months prior to trial initiation. The patients 
were selected through expert opinion to be included in the 
RE-SONA TE trial over the RE-MEDY trial if they were consid-
ered low-risk patients who were thought to be able to with-
stand placebo treatment. The primary outcome of the study 
was recurrent VTE or related death. Recurrent venous 
thromboembolism occurred in three patients in the dabiga-
tran group and 37 of the patients in the placebo group. These 
results were statistically significant, concluding that dabiga-
tran is more effective than placebo at preventing a recurrent 
VTE. Additionally, major bleeding occurred in 36 patients in the 
dabigatran group and only 12 patients within the placebo group 
(95 percent confidence interval (CI), 1.52 to 5.60 and P=0.001). 
Dabigatran dosing for DVT and PE is identical and instructs 
to administer one 150 mg capsule twice daily, directly fol-
lowing five to 10 days of parenteral anticoagulation thera-
py.14 Dabigatran is also dosed at 150 mg twice daily for the 
treatment of nonvalvular atrial fibrillation. For the postoper-
ative thromboprophylaxis following hip and knee replace-
ments, 110 mg of dabigatran is administered one to four 
hours after completion of surgery. If the patient is not started 
on dabigatran the day of surgery, it should be initiated when 
homeostasis is achieved and should be given 220 mg once 
daily. The maintenance dose is also 220 mg once daily and 
can be given for up to 28 to 35 days. 
Most common side effects associated with the use of 
dabigatran include hemorrhage and gastrointestinal symp-
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toms such as dyspepsia or gastritis-like symptoms.14 Less 
common adverse drug reactions include wound discharge, 
hematuria, anemia, hematoma, increased serum alanine 
aminotransferase (ALT), anaphylaxis and angioedema. 
Therefore, an allergy to dabigatran presents a large risk to 
patients. Additionally, it is important to determine the pa-
tient's renal function prior to the initiation of therapy and 
periodically throughout treatment or when clinically indicat-
ed. No exact recommendation for the frequency ofrenal func-
tion is provided. Routine coagulation tests, on the other 
hand, are not required but can be used if the medical team 
wishes to determine the levels of dabigatran in the blood and 
the level of therapy the patient is receiving. Such tests in-
clude activated partial thromboplastin time (aPTT), ecarin 
clotting test (ECT) or thrombin time (TT). 
Praxbind, generic name idarucizumab, is a monoclonal anti-
body which was developed as a reversal agent of 
dabigatran.14 Idarucizumab for Dabigatran Reversal (RE-
VERSE AD) was the study that lead to the approval ofidaruci-
zumab by the FDA.18 The RE-VERSE AD was a prospective 
cohort study that included 90 patients, split into two groups, 
who all received idarucizumab for the reversal of dabigatran. 
The first group consisted of patients who were taking 
dabigatran and experiencing uncontrollable or life-
threatening bleeding, while the second group was composed 
of patients who were in need of emergent surgery. The pri-
mary end point of the study was the maximum percentage of 
reversal for dabigatran by 5 g dose of idarucizumab given IV. 
The normalized results of the study concluded that 88 to 98 
percent of the patients experienced a reversal of dabigatran 
within minutes. In 79 percent of patients, unbound dabi-
gatran concentrations continued to remain below 20 ng/ml 
for 24 hours following idarucizumab administration. Within 
the study, only one patient experienced a thrombotic event 
after receiving the reversal agent. Due to the emergent need 
and high efficacy displayed, idarucizumab was approved by 
the FDA in 2015.19 
ldarucizumab is indicated as a reversal agent for dabigatran 
in the incidence of emergent surgery or if the patient has un-
controlled or life-threatening bleeding.14 The humanized 
monoclonal antibody fragment binds to both dabigatran and 
its acylglucuronide metabolites. Its affinity to dabigatran is 
approximately 350 times greater than that of thrombin, 
therefore inhibiting dabigatran within minutes. 
Idarucizumab adult dosing is 5 g IV as two separate 2.5 g 
doses, administered no more than 15 minutes apart.14 If the 
patient still has elevated coagulation parameters after the 
initial 5 g dose, an additional 5 g dose may be given. The 
most common side effects include delirium, headache, 
hypokalemia, constipation, pruritus, pneumonia and fever. 
Hypersensitivity symptoms may also occur such as rash, hy-
perventilation and pruritus. 
Rivaroxaban 
Rivaroxaban (Xarelto®) was approved as an anticoagulation 
therapy by the FDA in 2011. It was the first novel oral antico-
agulant (NOAC) approved, nearly 50 years after the approval 
of warfarin.20 Rivaroxaban is an oral direct factor Xa inhibi-
tor that works by prolonging activated thromboplastin time 
and increasing levels of anti-factor Xa. This medication is 
indicated for the treatment and prophylaxis of PE and DVT in 
patients who have undergone surgeries such as knee or hip 
replacement and patients diagnosed with nonvalvular atrial 
fibrillation. Currently, this therapy is being studied in the 
treatment of acute coronary syndromes. 
Rivaroxaban was compared to warfarin in a multi-center, 
randomized, double-blind, double-dummy, event-driven trial 
including 14,264 patients with nonvalvular atrial fibrillation 
with an increased risk of stroke in the ROCKET AF triaJ.21 The 
study recognized that vitamin K antagonists, like warfarin, are 
beneficial in patient populations with nonvalvular atrial fibril-
lation and increased risk of stroke. However, the increased 
monitoring, dosing adjustments, and food and drug interac-
tions, among other requirements, certainly demonstrated a 
need for a more convenient and manageable patient therapy. 
Rivaroxaban was targeted in this study as a once daily antico-
agulant with the potential to provide a more consistent, pre-
dictable and convenient therapy as opposed to warfarin. The 
study compared rivaroxaban with dose-adjusted warfarin in 
patients with the previously mentioned indications for the 
prevention of stroke and systemic embolism. 
Patients were identified as having a moderate-to-high risk of 
stroke if they had a history of previous stroke, transient is-
chemic attack or systemic embolism (SE) with either heart 
failure, left ventricular ejection fraction .s 35 percent, hyper-
tension, diabetes or were at least 75 years of age.21 Patients 
were then randomly assigned to either receive a fixed once 
daily dose of rivaroxaban in the evening (20 mg or 15 mg 
based on CrCl of 30 to 49 mL/min) or adjusted warfarin 
(target INR 2.0-3.0). The primary endpoints included hemor-
rhagic or ischemic stroke and systemic embolism. Secondary 
endpoints consisted of stroke, SE or death from cardiovascu-
lar causes; a composite including the previous or Ml; and 
individual components of the endpoints. Safety endpoints 
measured were composites of major and minor bleeding. 
Primary analysis was used to conclude rivaroxaban's nonin-
feriority to warfarin, and secondary analysis was used to 
conclude superiority. 
Over a span of three years, 14,264 patients were random-
ized.21 The median age of patients was 73 years, and patients 
also had substantial comorbid conditions including hyper-
tension, heart failure and diabetes. The per-protocol popula-
tion demonstrated significant differences in the primary 
outcome of stroke or systemic embolism (P<0.001). In the 
rivaroxaban group, only 188 events occurred in the 6,958 
patients representing 1. 7 percent/year, as opposed to 241 
events of the 7,004 patients in the warfarin group (2.2 per-
cent/year). Relevant nonmajor bleeding occurred in 1,475 
patients in the rivaroxaban group and 1,449 patients in the 
warfarin group, but the difference was not clinically signifi-
cant (P=0.44). Major bleeding rates also occurred at similar 
rates between the two treatment groups (P=0.58). Fatal 
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bleeding rates of intracranial hemorrhage were significantly 
lower in patients of the rivaroxaban group (0.5 percent ver-
sus 0.7 percent; P=0.02)). Decreases in hemoglobin and ma-
jor gastrointestinal bleeding were more common in the riva-
roxaban group than in the warfarin group. In evaluation of 
the secondary outcomes in the as-treated population, MI and 
death occurred less frequently in the rivaroxaban group than 
the warfarin group, but the difference was not clinically sig-
nificant. Results were similar in the intention-to-treat analy-
sis of secondary outcomes. Findings concluded that rivaroxa-
ban was noninferior to warfarin in primary analysis. In the 
analysis of patients receiving at least one dose of study drug, 
rivaroxaban was found to be superior to warfarin. 
Rivaroxaban dosing is specific for each individual indication. 
For the treatment of DVT and PE, it is recommended that the 
patient initially be started on lS mg twice daily with food for 
21 days, and then the patient should have their dose modi-
fied to 20 mg daily with food. 22 For the prevention of recur-
rent DVT and PE after six months of treatment, the suggested 
regimen is 20 mg once daily with food. For postoperative 
DVT thromboprophylaxis, it is recommended that therapy be 
initiated after hemostasis has been established six to 10 
hours postoperatively. In knee replacement, the recommend-
ed dosage is 10 mg once daily for 12 to 14 days (maximum 
3S days). For hip replacement, 10 mg once daily is appropri-
ate for 10 to 14 days (maximum 3S days). In the treatment of 
nonvalvular atrial fibrillations, 20 mg once daily with the 
evening meal is recommended. In cases of DVT and PE 
prophylaxis and treatment, dose reduction is recommended 
in older adults with CrCl between 30 and SO mL/min. If the 
CrCl is <30 mL/min, avoid use of rivaroxaban. In patients 
with nonvalvular atrial fibrillation, no dosage adjustment is 
necessary if the CrCl is >SO mL/min. If the CrCl is lS to SO 
mL/min, a dose reduction to lS mg is recommended. Use is 
discouraged if the CrCl is <lS mL/min or if the patient has 
end stage renal disease (ESRD) requiring dialysis. Beer's cri-
teria recommend a dose reduction in patients over the age of 
6S years with CrCI between 30 and SO mL/min and discour-
age use in patients with CrCI <30 mL/min. 
There is strong evidence to support the use of rivaroxaban in 
patients with atrial fibrillation and at least one additional 
stroke risk factor.20 Newer agents like rivaroxaban are indi-
cated for this condition due to the fact that routine lab moni-
toring is not required, which has become a key advantage for 
this therapy. It has been proven to be as effective as warfarin 
in this indication. Common side effects of rivaroxaban in-
clude bleeding, nausea and fatigue. 22 Renal function should 
be monitored at baseline and regularly during therapy.20 
Rivaroxaban has a black box warning stating that patients 
with nonvalvular atrial fibrillation may have an increased 
risk of thrombotic events if therapy is discontinued without 
adequate tapering of therapy through use of additional anti-
coagulation. Additionally, this warning states that patients 
who are receiving neuraxial anesthesia or are undergoing 
spinal puncture have an increased risk of epidural or spinal 
hematoma while taking rivaroxaban. This medication is con-
traindicated in patients with hypersensitivity to rivaroxaban 
or pathological bleeding. Rivaroxaban therapy is not recom-
mended in those patients who are pregnant or breastfeeding. 
One of the disadvantages of rivaroxaban over warfarin, aside 
from increased cost, is that there is currently no specific re-
versal agent for rivaroxaban in the event of severe hemor-
rhage.23 Upon suspected bleed associated with rivaroxaban, 
further evaluate the patient for signs and symptoms of blood 
loss, and consider the need for blood or blood products if 
necessary. Partial reversal has been seen in healthy volun-
teers after administration of prothrombin complex concen-
trates. One study demonstrated that prothrombin complex 
concentrates (Cofact) nearly neutralized the anticoagulant 
effects of rivaroxaban in healthy patients. However, further 
research needs to be targeted in this area.24 
Apixaban 
Apixaban (Eliquis®) is also a factor Xa inhibitor approved by 
the FDA in 2012.20 Apixaban is indicated for the prevention 
of SE and stroke in patient populations with nonvalvular atri-
al fibrillation. It can also be used for the treatment of DVT 
and PE, as well as thromboprophylaxis of postoperative DVT. 
Apixaban provides an advantage over warfarin due to warfa-
rin's narrow therapeutic range, drug-drug and drug-food 
interactions, and required monitoring. 
Apixaban inhibits formation of fibrin clots and platelet acti-
vation through direct reversible inhibition of both the free 
and bound form of factor Xa.2s It is predominantly metabo-
lized in the liver by CYP3A4/S enzymes and interacts with 
p-glycoprotein. Due to its metabolism by this enzyme, there 
are specific drug interactions with other inducers of CYP3A4 
and p-glycoprotein.20 Avoid apixaban in combination with 
CYP3A4 inducers like carbamazepine, phenytoin and rifam-
pin. It is not recommended in patients with severe liver im-
pairment, active pathological bleeding. prosthetic heart valves 
and those pregnant or breastfeeding. Additionally, use of non-
steroidal anti-inflammatory drugs and clopidogrel should be 
avoided with apixaban due to increased risk of bleeding 
In the ARISTOTLE trial, a randomized, double-blind, double-
dummy trial, patients were randomly assigned either apixa-
ban or dose-adjusted warfarin.26 The objective of this study 
was to prove the noninferiority of apixaban as compared to 
warfarin in reducing the incidence of stroke in patients with 
nonvalvular atrial fibrillation and at least another risk factor. 
Secondary outcomes were death from any cause and rate of 
MI. Patients enrolled in this study had at least two document-
ed episodes of atrial fibrillation or atrial flutter by electrocar-
diogram. Other risk factors included age of at least 7S years, 
previous incidence of stroke, transient ischemic attack, heart 
failure, diabetes or hypertension. This trial also measured 
the safety outcome of major bleeding as well as whether 
apixaban was superior to warfarin with respect to reduction 
of stroke and reduction in major bleeding. 
Apixaban was given twice daily in either 2.S mg or S mg dos-
es.26 There was a significant difference in death between the 
apixaban and warfarin treatment groups. The rate of death in 
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the apixaban group was 3.52 percent as compared to 3.94 
percent in the warfarin group (p=0.047). Stroke or SE 
occurred in 212 patients in the apixaban group and 265 pa-
tients of the warfarin group, showing that apixaban demon-
strated a significant lower incidence of the primary outcomes 
(p<0.001). Hemorrhagic stroke was 49 percent lower in the 
apixaban group than the warfarin group. Ischemic stroke 
was 8 percent lower in the apixaban group than the warfarin 
group. Approximately 84 patients in the apixaban group ex-
perienced fatal or disabling stroke as compared to 117 pa-
tients in the warfarin group (p=0.01). Secondary outcomes 
also showed similar differences among treatment groups. 
Death from any cause (3.52 percent versus 3.94 percent), 
rate of death from cardiovascular events (1.80 percent ver-
sus 2.02 percent) and rate of death from noncardiovascular 
events (1.14 percent vs. 1.22 percent) was significantly lower 
in the apixaban group than warfarin group. 
The rate of MI was lower in the apixaban group, but the dif-
ference was not statistically significant (P=0.37).26 Major 
bleeding occurred at a statistically significantly higher rate in 
the warfarin group than the apixaban group (p<0.001). Ac-
cording to the Global Use of Strategies to Open Occluded Cor-
onary Arteries (GUSTO) criteria for bleeding, there was a 
greater reduction in risk of bleeding in the apixaban group. 
Fewer patients experienced intracranial hemorrhage and 
overall major bleeding in the apixaban group than the warfa-
rin group. Rates of adverse events were similar among 
groups. Overall, this study concluded that there was a signifi-
cant reduction in risk of stroke or SE in treatment with apixa-
ban over treatment with warfarin. No unexpected side effects 
were noted in the apixaban group. While the authors noted 
that warfarin is still extremely efficacious in the prevention 
of stroke in patients with atrial fibrillation, they identified 
that apixaban did not have many of the issues seen in 
warfarin therapy. The dose that was most efficacious for the 
prevention of stroke in these study patients was 5 mg twice 
daily. This study concluded that apixaban was noninferior to 
warfarin in preventing the primary outcomes. 
Apixaban is normally dosed at 5 mg twice daily for atrial fi-
brillation.zo It is recommended that the dose be reduced to 
2.5 mg twice daily if the patient is 80 years of age or older, 
has a bodyweight of 132 pounds or less or has a serum creat-
inine level of 1.5 mg/dL or above. Currently there is no data 
for dosing in patients on dialysis with a CrCI < 15 mL/min or 
patients with liver impairment. For the treatment of DVT and 
PE 10 mg twice daily for seven days followed by 5 mg twice 
daily maintenance is recommended.ZS To reduce the risk of 
recurrence of DVT and PE, 2.5 mg twice daily is recommend-
ed for at least six months following treatment for DVT. In 
postoperative prophylaxis, initiate 2.5 mg twice daily 12 to 
24 hours postoperatively in both knee and hip replacement. 
The most common adverse effect of apixaban is bleeding. 
However, clinically relevant bleeding comprises only a small 
portion of this adverse event.zo,zs Similar to rivaroxaban, 
there is no specific reversal agent for apixaban at this time.zo 
The clinician and patient should monitor for signs of bleed-
ing during treatment. Currently, studies are being conducted 
to investigate potential reversal agents in patients receiving 
this therapy.24 We should expect to see more research on this 
topic in the future. 
Apixaban is best suited for patients who are unable or un-
willing to adhere to the monitoring parameters associated 
with vitamin K antagonists like warfarin.27 While warfarin 
requires strict monitoring of specific blood parameters, apix-
aban does not require such monitoring. This criteria should 
be considered when selecting the appropriate therapy for 
patients eligible for anticoagulation therapy. 
Role of the Pharmacist 
With the recent approval of advanced anticoagulation thera-
py, the pharmacist must make it a priority to keep up to date 
on changes.zs Additionally, the pharmacist must be able to 
identify the advantages and disadvantages of newer thera-
pies as compared to traditional therapies like warfarin in 
making patient specific recommendations. Refer to Table 1 
as a guide in recommending appropriate anticoagulation 
therapy. Pharmacists certainly continue to play a large role 
in management of patients requiring anticoagulation thera-
py. For pharmacists specifically working in the area of anti-
coagulation, such as clinics, a national certification exam is 
available through the National Certification Board for Antico-
agulation Providers. Pharmacists will continue to play a cru-
cial role in assessing patients for appropriate therapy and 
adjusting accordingly to provide exceptional patient care. 
Impact of Patient Care and Counseling Points 
Anticoagulation therapy provides a large area for pharmacist 
intervention. Anticoagulation therapy is common, especially in 
patients suffering from congenital heart defects, heart valve 
replacements, surgery and other heart and coagulation related 
disorders.29 Patients receiving anticoagulation therapy who 
become pregnant need to take special precautions and be 
monitored. The cardiologist and the obstetrician of the patient 
should address her specific and individualized management. 
While frequent monitoring is a drawback of warfarin use, 
some competent, well-controlled patients may be eligible to 
self-monitor their INR at home.zo Point-of-care monitors, 
which are normally used in clinics and physicians' offices, 
may be provided to patients for home use. Patient self-
testing has demonstrated an increase in INR control, de-
creased thromboembolic events, improved quality of life and 
patient satisfaction with treatment. Self-testing may not be 
appropriate in all patients taking warfarin. Patients should 
not be considered for self-testing if they do not demonstrate 
competency, are treated with warfarin for less than six 
months, have atypical INR target ranges, have intellectual 
impairment, have a known drug or alcohol problem or have 
language barriers that would impede with communication. It 
is important to consider these criteria when deciding if a pa-
tient is eligible for self-monitoring of INR. 
Table 2 identifies important counseling points for pharma-
cists for each individual therapy. It is crucial to educate these 
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Table 1. Comparison of Anticoagulation Therapy for Pharmacist Recommendation.6,10,13-14 
Anticoagulant Dosing FDA Approved Renal dosing Monitoring Indications 
Once Prophylaxis and treat- No dosage adjustment necessary.10 INR should be monitored 
daily; ment ofthromboem- However, patients with renal failure at least every one to four 
with or bolic disorders and have an increased risk of bleeding weeks.10 When products 
without embolic complications complications; monitor closely. that affect warfarin are 
food10 arising from Afib or initiated, discontinued, 
Warfarin cardiac valve replace- or taken irregularly, 
ment; adjunct to re- additional INR testing 
duce risk of systemic should be performed. 
embolism after myo-
cardial infarction.10 
Once DVT prophylaxis and DVT&PE: Routine lab monitoring 
daily; treatment; PE prophy- CrCl > 30 mL/min - no dose adjust- not required 
with food !axis and treatment; mentAvoid use in CrCI < 30 mL/min 
nonvalvular Afib Nonvalvular Afib: Monitor renal and hepatic 
CrCl > SO mL/min - no dose function 
adjustment 
CrCI lS to SO mL/min, reduce dose 
Rivaroxaban to lS mg once daily with evening 
meal. 
Avoid use ifCrCl < lS mL/min 
Postoperative thromboprophylaxis: 
CrCl > SO mL/min - no adjustment 
Use with caution in CrCl 30 to SO 
mL/min 
Avoid use in CrCl < 30 mL/min 
Twice DVT prophylaxis and DVT&PE: Routine lab monitoring 
daily; treatment; PE prophy- No dose adjustment not required 
with or !axis and treatment; 
without nonvalvular Afib Nonvalyular Afib: Not recommended in 
food sCR < 1.S mg/dL no adjustment severe liver impairment 
Apixaban 
necessary unless > 80 years of age 
and body weight.$_ 60 kg - reduce 
dose to 2.6 mg twice daily. 
sCr.:::. LS mg/dL and either.:::. 80 
years of age or body weight< 60 kg -
2.5 mg twice daily 
Twice DVT treatment and CrCI > 30 mL/min - no adjustment Routine monitoring not 
daily; prophylaxis; nonvalvu- unless CrCl, SO mL/min and patient required. Can use aPTT, 
with or Jar AFib; postoperative is receiving concomitant P-gp ECT or TT if desired 
without thromboprophylaxis inhibitors - avoid coadministration 
Dabigatran food 
Avoid use ifCrCl <30 ml/min 
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Table 1 (continued). Comparison of Anticoagulation Therapy for Pharmacist Recommendation.6,10,13-14 
Reversal Agent Adverse Effects Interactions Procedure Considerations 
Vitamin K, and in severe bleed- Increased risk for Many drug and food interactions, Hold S days prior to 
ing complications PCC or FFP is bleeding10 but dose can be adjusted for inter- surgery.10 If urgent 
also used6.10,13 actions.10 procedure, may administer 
low-dose IV or oral vitamin 
K. 
Continue warfarin during 
minor dental and dermato-
logical procedures or 
cataract surgery. 
No specific reversal agent Fatigue, nausea, CYP3A4 and P-gp drug interactions Hold 24 hours prior to 
increased bleeding surgery 
May consider PCC, activated risk 
PCC or recombinant factor VIia Longer cessation may be 
required based on clinical 
Do NOT use dialysis judgment 
No specific reversal agent Bleeding, nausea, CYP3A4 and P-gp drug interactions Hold 24 to 48 hours prior 
bruising to surgery 
May consider PCC, activated 
PCC or recombinant factor VIia 
for major bleeding 
Do NOT use dialysis 
Activated charcoal may be used 
if ingestions within 2-4 hours of 
presentation 
Idarucizumab Hemorrhage, dys- P-gp drug interactions CrCl ;;::SQ mL/minute: Hold 
pepsia 1 to 2 days prior to surgery 
CrCl <SO mL/minute: Hold 
3 to S days prior to surgery 
Consider holding more 
than S days before major 
surgery spinal puncture, or 
insertion of a spinal or 
epidural catheter or port 
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Table 2. Counseling Guide for Pharmacists in Anticoagulation Therapy.10,14,22,2s 
Anticoagulant Indication Monitoring/ Expectat ions Therapy 
The medication is used to The patient may notice more bleeding or bruising. 
treat blood clots and is Common side effects include fatigue, nausea or abdominal pain. 
used to thin the blood so 
more clots will not form. This medication can cause severe bleeding-it's important to monitor for 
signs of extreme bruising and bleeding like bloody stools, blood in the 
Warfarin urine, excessive dizziness and severe weakness. 
If the patient falls and/or hits their head, advise patient to seek medical 
attention immediately. 
This medication requires frequent blood work monitoring (lNR) by the 
physician. It is important to keep these appointments. 
The medication is used to The patient may notice more bleeding or bruising. 
treat blood clots and is Spinal or epidural procedures are more likely to have bleeding issues in 
used to thin the blood so 
more clots will not form. that area. While this effect is rare, if it does happen it can cause paralysis in some cases. Consult physician. 
Rivaroxaban Risk of bleeding is increased with aspirin or NSAIDs. 
While there is no routine monitoring for this drug, it is important to have 
regular blood work done. 
If the patient falls and/or hits their head, advise patient to seek medical 
attention immediately. 
The medication is used to The patient may notice more bleeding or bruising. 
treat blood clots and is Other common side effects of this medication include nausea and anemia. 
used to thin the blood so 
more clots will not form. Spinal or epidural procedures are more likely to have bleeding issues in 
that area. While this effect is rare, if it does happen it can cause paralysis 
in some cases. Consult physician. 
Apixaban Risk of bleeding is increased with aspirin or NSAIDs. 
While there is no routine monitoring for this drug, it is important to have 
regular blood work done. 
If the patient falls and/ or hits their head, advise patient to seek medical 
attention immediately. 
The medication is used to The patient may notice more bleeding or bruising. 
treat blood clots and is Other common side effects of this medication include upset stomach or 
used to thin the blood so 
more clots will not form. heartburn. 
Spinal or epidural procedures are more likely to have bleeding issues in 
that area. While this effect is rare, if it does happen it can cause paralysis 
Dabigatran 
in some cases. Consult physician. 
Risk of bleeding is increased with aspirin or NSAIDs. 
While there is no routine monitoring for this drug, it is important to have 
regular blood work done. 
If the patient falls and/or hits their head, advise patient to seek medical 
attention immediately. 
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Missed Dose 
If a dose is missed, take the dose as soon as patient thinks of it if 
on the same day as the missed dose. 
If it is close to the time of the next dose, skip to missed dose and 
go back to normal schedule. 
Do not take extra doses or more than one dose in the same day. 
Don't stop taking this medication unless directed by a doctor. 
Stopping the drug increases risk of blood clots. 
For dosing 15 mg twice daily and miss a dose, take the missed 
dose as soon as patient thinks of it to get 30 mg in for the day. In 
this case, the patient can take two doses at the same time. Return 
to normal time the following day. 
For all other doses: If a dose is missed, take the dose as soon as 
patient thinks of it if on the same day as the missed dose. If it is 
close to the time of the next dose, skip to missed dose and go back 
to normal schedule. Do not take extra doses or more than one 
dose in the same day. 
Don't stop taking this medication unless directed by a physician. 
Stopping the drug can increase risk of blood clots. 
If a dose is missed, take the dose as soon as patient thinks of it if 
on the same day as the missed dose. 
If it is close to the time of the next dose, skip the missed dose and 
go back to normal schedule. 
Do not take extra doses or more than one dose in the same day. 
Don't stop taking this medication unless directed by a physician. 
Stopping the drug can increase risk of blood clots. 
If a dose is missed, take the dose as soon as patient thinks of it if 
on the same day as the missed dose. 
If it is less than 6 hours until the next dose, skip the dose and. 
return to normal schedule. 
Do not take extra doses or more than one dose in the same day. 
Don't stop taking this medication unless directed by a physician. 
Stopping the drug can increase risk of blood clots. 
Other Precautions 
The patient may notice bleeding of the gums or bleeding 
while shaving. Recommend a soft bristle toothbrush or 
electric razor. 
Inquire about new medications or dietary supplements. 
Many foods may interact with this medication. Keep the 
diet consistent to minimize fluctuations in lab values. 
Avoid excessive consumption ofleafy greens, green tea 
and alcohol. 
The patient may notice bleeding of the gums or bleeding 
while shaving. Recommend a soft bristle toothbrush or 
electric razor. 
Take this medication with food and a full glass of water in 
the evening. 
There are no food interactions with this medication. 
The patient may notice bleeding of the gums or bleeding 
while shaving. Recommend a soft bristle toothbrush or 
electric razor. 
Take this medication with or without food. 
There are no food interactions with this medication. 
The patient may notice bleeding of the gums or bleeding 
while shaving. Recommend a soft bristle toothbrush or 
electric razor. 
Take this medication with or without food and with a full 
glass of water. 
Do not store this medication in a pill box or organizer. 
It is important to leave this medication in its original 
container. 
Throw away any unused capsules after four months. 
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patients to manage their conditions and reduce their risk of 
stroke and other cardiovascular events. 
Economic Concerns 
The cost of these new anticoagulant medications is offset by 
both adverse effect mitigation and the economic impact of 
cardiovascular events such as stroke. In 2008, an alarming 
780,000 patients experienced a stroke, costing an estimated 
$65.5 billion. While it is important to note that not all strokes 
are caused by atrial fibrillation, prevention of stroke second-
ary to atrial fibrillation through anticoagulation therapy is 
crucial. The economic burden of bleeding in patients receiv-
ing anticoagulation therapy is limited in comparison to the 
costs associated with stroke. In 2011, studies estimated the 
cost of these bleeding events to be around $35,000; however, 
the severity of the bleed will ultimately determine the true 
impact. 
For over a decade, warfarin therapy has consistently been 
more cost-effective compared to aspirin therapy.3o Warfarin 
is cost-effective in patients at least 65 years of age with atrial 
fibrillation and at least one additional risk factor for stroke. 
These risk factors include history of transient ischemic at-
tack (TIA), hypertension, diabetes and heart disease. Even in 
patients without additional risk factors for stroke, the cost-
effectiveness of warfarin over aspirin remains high. 
Dabigatran is certainly more expensive than warfarin due to 
a higher acquisition cost, raising the question of whether or 
not it is a cost-effective option as compared to warfarin.3o 
One model studied the cost-effectiveness of dabigatran using 
CHADS2 score based on the presence or absence of risk fac-
tors. Dabigatran 150 mg dosed twice daily was determined to 
be cost-effective in patients older than 65 years who had at 
least one point based on their CHADS2 score with no contra-
indications against dabigatran therapy. However, 110 mg 
daily was not determined to be cost-effective. 
Another model by Shah and Gage estimated the cost of 
dabigatran at approximately $9 per day.3o Cost-effectiveness 
was measured over 20 years of treatment. In patients with a 
CHADS2 score of 0, aspirin was preferred over dabigatran 
therapy in terms of cost-effectiveness. In patients with a 
CHADS2 score of 1 or 2, warfarin was preferred over 
dabigatran unless the patient was at high risk of bleeding or 
was rarely within therapeutic range while on warfarin. If the 
patient had a CHADS2 score of 3 or higher, 150 mg of 
dabigatran was preferred in terms of cost-effectiveness. This 
recommendation stands regardless of bleeding risk or time 
within target INR. Dabigatran dosed at 110 mg twice daily 
was determined not to be cost-effective in this model. The 
third model studying the cost-effectiveness of dabigatran 
compared dosing of 150 mg in patients who had previously 
experienced a stroke or TIA This study determined that 150 
mg twice daily was not cost-effective as compared to warfarin. 
Rivaroxaban's cost-effectiveness was studied in patients at a 
high risk of stroke.30 Over a time period of 35 years or until 
death, it was found that rivaroxaban 20 mg daily is more 
cost-effective than warfarin therapy if the patient was at 
least 65 years of age and at a high risk of stroke. The authors 
noted that this effectiveness was also sensitive to change in 
risk of stroke. 
Apixaban's cost-effectiveness was studied in three separate 
models.3o In the first Markov model, the cost-effectiveness of 
apixaban was studied compared to aspirin in patients 70 
years of age with atrial fibrillation, high risk of stroke, low 
risk of bleeding or not suitable for warfarin therapy. Apixa-
ban was more costly than aspirin in the first year. However, 
after 10 years the data showed a reversal in this conclusion. 
Apixaban became more cost-effective over longer periods 
of time. The second Markov model studied the cost-
effectiveness of apixaban compared to warfarin in patients 
65 years of age with atrial fibrillation and a CHADS2 score of 
2. Apixaban was determined to be more cost-effective over a 
timeline of 35 years. In a third model, the subject of study 
was the cost reduction of clinical events such as major bleed-
ing associated with anticoagulation oral therapy. It was de-
termined that the medical cost reduction was significantly 
more with newer anticoagulation therapy compared to war-
farin. The yearly medical cost of these events with 
dabigatran, rivaroxaban and apixaban were $1,905; $1,995; 
and $1,598, respectively, versus $2,084 with warfarin. 
Future of Anticoagulation Therapy 
In the future, pharmacists should expect to see further ad-
vancements in anticoagulation. Specifically, studies are cur-
rently being conducted to potentially identify a reversal 
agent for rivaroxaban and apixaban.24 While there have been 
numerous advancements in medications in the last two dec-
ades, it is expected that there will be an increased focus on 
disease prevention and patient safety with this therapy. This 
focus is primarily due to quality care assessments and their 
direct impact on hospital accreditation and reimbursement. 
Overall, anticoagulation therapy provides a number of op-
portunities for drug development, further improvements in 
disease state management and promotion of health care pro-
fessional collaboration. 
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